Company profile: Eikonoklastes
1.1 - Company Overview
Company description
- Provider of gene therapies that increase Caveolin-1 expression in neurons to address neurodegenerative diseases, including ET-101, designed to overexpress Caveolin-1 and potentially benefit patients with ALS, Parkinson’s, Huntington’s, MS, and dementia, and SynCav1, which enhances neuroprotection and neuroplasticity for a wide range of neurodegenerative conditions.
Products and services
- SynCav1: A gene therapy-based product that increases Caveolin-1 expression to enhance neuroprotection and neuroplasticity, aimed at treating a wide range of neurodegenerative diseases
- ET-101: A neuron-targeted gene therapy platform engineered to overexpress Caveolin-1 in neurons, potentially benefiting ALS, Parkinson’s, Huntington’s, MS, and dementia patients
- Innovative Medicines Advancement: Program-scale effort by Eikonoklastes rapidly advancing innovative medicines for numerous areas of significant unmet medical need
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Eikonoklastes
Compass Therapeutics
HQ: United States
Website
- Description: Provider of immune system–targeting therapeutics and antibody engineering platforms. Pipeline: CTX-009, a DLL4/VEGF-A bispecific showing benefit in colorectal and gastric cancers; CTX-471, a CD137 agonist for melanoma with U.S. studies planned H2 2024; and CTX-8371, a PD-1/PD-L1 bispecific in preclinical development for solid tumors. Platforms: StitchMabs for bispecifics, common light chain discovery, and human display for antibody tuning.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Compass Therapeutics company profile →
Nereus Pharmaceuticals
HQ: United States
Website
- Description: Provider of therapeutics discovery and development focused on oncology, infectious diseases, and inflammation, leveraging marine microbiology technologies to identify and develop drug candidates, including NPI-2358, a tumor vascular disrupting agent.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nereus Pharmaceuticals company profile →
Enveric Biosciences
HQ: United States
Website
- Description: Provider of patient-first biotechnology solutions developing rigorously tested, novel cannabinoid medicines and mental health drug candidates, including EB-003, a neuroplastogen for severe disorders without inducing hallucinations; EB-002, a synthetic prodrug of psilocin being studied for psychiatric disorders with altered metabolic and pharmacokinetic properties; and Psybrary, an AI-optimized platform and portfolio of new chemical entities.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Enveric Biosciences company profile →
T3 Pharmaceuticals
HQ: Switzerland
Website
- Description: Provider of innovative bacterial cancer therapies using engineered live bacteria to deliver immune-modulating proteins directly to cancer cells and the tumor micro-environment. Offers a proprietary bacterial cancer therapy platform and develops T3P-Y058-739, a lead candidate delivering proteins into solid tumors to induce a specific immune response.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full T3 Pharmaceuticals company profile →
Linnaeus Therapeutics
HQ: United States
Website
- Description: Provider of development-stage cancer therapeutics, including LNS8801, an orally bioavailable, highly specific G protein-coupled estrogen receptor (GPER) agonist that depletes c-Myc protein levels, shows antitumor activities in preclinical cancer models, and is being tested in clinical trials as a monotherapy and with pembrolizumab.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Linnaeus Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Eikonoklastes
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Eikonoklastes
2.2 - Growth funds investing in similar companies to Eikonoklastes
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Eikonoklastes
4.2 - Public trading comparable groups for Eikonoklastes
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →